Jolanta Nowak

Jolanta Nowak

Auto-generated profile, based on publicly available information

Jolanta Nowak

3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2010 in European Heart Journal
Verified
Journal Article
Open access
PDF file
EJEwa Jankowska
Ewa Jankowska
PRPiotr Rozentryt
Piotr Rozentryt
AWAgnieszka Witkowska
Agnieszka Witkowska
JNJolanta Nowak
Jolanta Nowak
OHOliver Hartmann
Oliver Hartmann
PPPiotr Ponikowski
Piotr Ponikowski
Beyond erythropoiesis, iron is involved in numerous biological processes crucial for maintenance of homeostasis. Patients with chronic heart failure (CHF) are prone to develop iron deficiency (ID), and iron supplementation improves their functional status and quality of life. We sought to examine the relationship between ID and survival in patients with systolic CHF. In a prospective observational study, we evaluated 546 patients with stable systolic CHF [age: 55 ± 11 (mean ± standard deviation) years, males: 88%, left ventricular ejection fraction: 26 ± 7%, New York Heart Association (NYHA) class (I/II/III/IV): 57/221/226/42]. Iron deficiency was defined as: ferritin <100 µg/L, or 100–300 µg/L with transferrin saturation <20%. The prevalence of ID was 37 ± 4% [±95% confidence intervals (CI)] in the entire CHF population (32 ± 4 vs. 57 ± 10%—in subjects without vs. with anaemia defined as haemoglobin level <12 g/dL in women and <13 g/dL in men, P < 0.001). In a multiple logistic model, ID was more prevalent in women, those in the advanced NYHA class, with higher plasma N-terminal pro-type B natriuretic peptide and higher serum high-sensitivity C-reactive protein (all P < 0.05). At the end of follow-up (mean duration: 731 ± 350 days), there were 153 (28%) deaths and 30 (6%) heart transplantations (HTX). In multivariable models, ID (but not anaemia) was related to an increased risk of death or HTX (adjusted hazard ratio 1.58, 95% CI 1.14–2.17, P < 0.01). In patients with systolic CHF, ID is common and constitutes a strong, independent predictor of unfavourable outcome. Iron supplementation may be considered as a therapeutic approach in these patients to improve prognosis.

1 November 2011 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
EJEwa Jankowska
Ewa Jankowska
PRPiotr Rozentryt
Piotr Rozentryt
AWAgnieszka Witkowska
Agnieszka Witkowska
JNJolanta Nowak
Jolanta Nowak
OHOliver Hartmann
Oliver Hartmann
PPPiotr Ponikowski
Piotr Ponikowski

1 September 2010 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
PRPiotr Rozentryt
Piotr Rozentryt
SHStephan von Haehling
Stephan von Haehling
MLMitja Lainscak
Mitja Lainscak
JNJolanta U. Nowak
Jolanta U. Nowak
Kamyar Kalantar-ZadehKamyar Kalantar-Zadeh
Kamyar Kalantar-Zadeh
Stefan D. AnkerStefan D. Anker
Stefan D. Anker
The prevalence of cardiac cachexia in chronic heart failure is approximately 5% to 15% and 18‐month mortality rates can reach 50%. Treatment with angiotensin‐converting enzyme inhibitors and beta‐blockers may confer some benefit but no proven therapy exists. We tested the effects of an oral nutritional supplement in cachectic patients with heart failure. This was a prospective, randomized, double‐blind, placebo‐controlled pilot study which randomized 29 patients to a high‐caloric (600 kcal) high‐protein (20 g) oral nutritional supplement or placebo for a duration of 6 weeks in addition to the patients’ usual food intake. At baseline, 6 weeks, and 18 weeks, we measured body weight, quality of life, body composition, heart function, laboratory parameters, and exercise performance. Edema‐free body weight increased in 19 of 20 patients receiving intervention at 6 weeks and in 17 of 19 patients at 18 weeks with an average weight gain of 2.0 ± 1.7 kg (3.1 ± 2.4%, p = 0.0001) and 2.3 ± 3.1 kg (3.6 ± 4.7%, p = 0.007) at 6 and 18 weeks, respectively. Most of the weight gain was fat tissue with an absolute gain of 1.5 ± 1.7 kg (p = 0.003) and 1.6 ± 2.7 kg (p = 0.008). A significant improvement in quality of life and decrease in serum levels of tumor necrosis factor‐α were observed (p < 0.05 for both). We demonstrated the feasibility of oral nutritional supplement in cachectic patients with heart failure and significant clinical benefit in terms of body size and body composition, laboratory parameters, and quality of life (www.clinicaltrials.gov identifier NCT00654719).

13 May 2009 in JAMA
Verified
Journal Article
Open access
PDF file
EJEwa Jankowska
Ewa Jankowska
PRPiotr Rozentryt
Piotr Rozentryt
BPBeata Ponikowska
Beata Ponikowska
OHOliver Hartmann
Oliver Hartmann
DKDorota Kustrzycka-Kratochwil
Dorota Kustrzycka-Kratochwil
PPPiotr Ponikowski
Piotr Ponikowski
Estrogens have numerous biological effects in men1-3 and have a complex effect on the normal cardiovascular system.4-6 Several studies have identified a role for estrogens in the pathophysiology of cardiovascular disease in men.4-6

1 March 2006 in The American Journal of Cardiology
Verified
Journal Article
Closed access
RWRomuald Wojnicz
Romuald Wojnicz
KWKrzysztof Wilczek
Krzysztof Wilczek
ENEwa Nowalany-Kozielska
Ewa Nowalany-Kozielska
BSBożena Szyguła-Jurkiewicz
Bożena Szyguła-Jurkiewicz
JNJolanta Nowak
Jolanta Nowak
MRMarius M. Rozek
Marius M. Rozek

1 September 2019 in Atherosclerosis
Verified
Journal Article
Closed access
KDKrzysztof Dyrbuś
Krzysztof Dyrbuś
MGMariusz Gąsior
Mariusz Gąsior
PDPiotr Desperak
Piotr Desperak
TOTadeusz Osadnik
Tadeusz Osadnik
JNJolanta Nowak
Jolanta Nowak
MBMaciej Banach
Maciej Banach